Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.33 |
| ▸ | MGMT | P16455 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22657962 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL14713434 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL29444978 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL17319197 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL19725973 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL23194379 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL14981499 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL16329452 | 1.00 | CRBN (0.33) | CRBNMGMTGAA | |
| SCHEMBL16329449 | 0.99 | GAA (0.33) | CRBNMGMTGAA | |
| SCHEMBL26846799 | 0.93 | CRBN (0.36) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4623081-A2 | SPLIT SYNTHESIS OF LONG RNAS | Prime Medicine, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12377175-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250214985-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250163040-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-12268759-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| US-12258339-B2 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | CORNELL UNIVERSITY (US) | 2025-03-25 | — | — | US | disclosed |
| US-12103922-B2 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | CORNELL UNIVERSITY (US) | 2024-10-01 | — | — | US | disclosed |
| WO-2024112876-A2 | SPLIT SYNTHESIS OF LONG RNAS | PRIME MEDICINE, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240050599-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2024-02-15 | — | — | US | disclosed |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230114130-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | COMELL UNIVERSITY (US) | 2023-04-13 | — | — | US | disclosed |
| EP-4143200-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GlycoMimetics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220274974-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2022-09-01 | — | — | US | disclosed |
| US-20220185803-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220177461-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2022-06-09 | — | — | US | disclosed |
| US-11285227-B2 | Trifunctional constructs with tunablepharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2022-03-29 | — | — | US | disclosed |
| US-11279698-B2 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | CORNELL UNIVERSITY (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285227-B2 | Trifunctional constructs with tunablepharmacokinetics useful in imaging and anti-tumor therapies | MC2R, OGFR, GLS | CRBN 3588/4885MGMT 2237/4885GAA 3194/4885 |
| US-20220185803-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | CRBN 2855/4885MGMT 267/4885GAA 226/4885 |
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | SIGLEC7, SIGLEC9, CD47 | CRBN 1918/4885MGMT 2590/4885GAA 676/4885 |
| US-20220274974-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, KLK3, FOLH1 | CRBN 2767/4885MGMT 380/4885GAA 135/4885 |
| US-20220177461-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | CRBN 2855/4885MGMT 267/4885GAA 226/4885 |
| US-20230114130-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, KRAS | CRBN 2239/4885MGMT 1225/4885GAA 2902/4885 |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | CRBN 1374/4885MGMT 2456/4885GAA 3329/4885 |
| US-20240050599-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | CRBN 1374/4885MGMT 2456/4885GAA 3329/4885 |
| US-11279698-B2 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | PSMA1, FOLH1, KLK3 | CRBN 2855/4885MGMT 267/4885GAA 226/4885 |
| US-12377175-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | CRBN 1374/4885MGMT 2456/4885GAA 3329/4885 |
| US-20250163040-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | CRBN 2855/4885MGMT 267/4885GAA 226/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | CRBN 3368/4885MGMT 3249/4885GAA 2425/4885 |
| US-12258339-B2 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | PSMA1, FOLH1, KLK3 | CRBN 2855/4885MGMT 267/4885GAA 226/4885 |
| US-12268759-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | CRBN 1374/4885MGMT 2456/4885GAA 3329/4885 |
| US-12103922-B2 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | PSMA1, KLK3, FOLH1 | CRBN 2767/4885MGMT 380/4885GAA 135/4885 |
| US-20250214985-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | CRBN 2855/4885MGMT 267/4885GAA 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.